Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

>Dr. Philip M. Brown, senior vice president of clinical development at Lexicon.  "Rapid improvement in multiple parameters of diabetes, meaningful weight loss, a favorable safety profile and the fact that LX4211-treated patients exhibited improvements in clinically-important metabolic and cardiovascular parameters within four weeks on a single agent is remarkable."

The recently completed study was a four-week, randomized, double-blind, placebo-controlled study in 36 patients with type 2 diabetes.  Patients were randomized to receive either placebo (n=12) or LX4211, 150 mg (n=12) or 300 mg (n=12), once daily for 28 days.  Patients were sequestered, provided a controlled diet and monitored closely throughout the study period.

There was a marked decrease in fasting plasma glucose throughout the treatment period in both dose groups, with reductions at week four of 53.4 mg/dl and 65.9 mg/dl in the 150 mg and 300 mg dose groups, respectively, as compared to 15.1 mg/dl for placebo.  These decreases in fasting plasma glucose relative to placebo were statistically significant for both LX4211 dose groups (p=0.001 and p<0.001, respectively).  Notably, a substantial percentage (42%) of patients in the 300 mg dose group achieved fasting plasma glucose levels of <105 mg/dl at week four of dosing as compared to placebo (p=0.037).

Importantly, after only four weeks of dosing, average percent hemoglobin A1c (HbA1c), a measure of blood glucose levels over time, was significantly reduced by 1.15 in the 150 mg dose group (p=0.036) and by 1.25 in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group.  HbA1c levels were reduced to less than or equal to 7% for half the patients in both dose groups; baseline levels were 8.22%, 8.50% and 8.20% for the 150 mg, 300 mg, and placebo groups, respectively. Patients in both dose groups also exhibited significantly improved glucose tolerance in resp
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China ... store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... and policy support, China,s orthopedic ... with total market size rising from 3.28 billion yuan ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
(Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According to ... this is a comprehensive program that teaches people how ... peripheral neuropathy without medications. This program also provides ... symptoms of peripheral neuropathy , including numbness, prickling, burning, ... its review that this home treatment program can help ...
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... 12, 2014 The report, "Phthalic Anhydride ... Market by Application & Geography – Trends & Forecast ... analysis and forecasting of market volume and value. The ... derivatives separately. The market of phthalic anhydride is projected ... to $8,415.89 million by 2018, with a CAGR of ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... nearly 2 hours in the waiting room of the hospital, was ... ,Beatrice Vance, 49, died of a heart attack, but her death ... care that a reasonable person would have exercised in this situation.' ... Waukegan. A spokeswoman of that center refused to comment on the ...
... new backpack your son or daughter just got for the ... for a lifetime of back and neck ailments if not// ... of the Department of Occupational Therapy at University of the ... even they can’t take the day after day stress caused ...
... American inner city schoolgirls have been developing culturally ... measure// which children are likely to take offense ... the cartoons over traditional written descriptions of provocative ... Ph.D., a pediatric psychologist at The Children's Hospital ...
... and the American Society for Therapeutic Radiology and Oncology ... comes to// prostate cancer awareness, screening and their treatment ... cases of prostate cancer will be diagnosed in the ... screening for prostate cancer is relatively easy. ...
... to officials on Friday, a courthouse in New Jersey was ... the workers and it will remain shut at// least until ... of the woman’s medical condition, partly due to privacy rules. ... be critical. She is an independent title searcher with the ...
... new treatment for malaria has been developed with the help ... lives in Africa. A system based on fluid// replacement for ... College in London in collaboration with the Wellcome Trust Kenya ... lives of millions of kids, who die every year due ...
Cached Medicine News:Health News:Lighten Up! Heavy Backpacks a Weighty Load for Children to Bear 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 3Health News:Do You Know the Signs and Symptoms of Prostate Cancer? 2Health News:A Novel approach in Malaria treatment 2
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... The Diagnostic Automation, Inc.. (DAI) Measles ... for the detection and quantitative determination of ... human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
... osmolality at room temperature with the sample ... are cryoscopic artifacts due to high viscosity, ... with freezing point determinations. The superbly accurate ... osmometer has a much broader range of ...
... a glucocorticoid produced by the adrenal cortex ... is secreted with a circadian periodicity, and ... morning. Cortisol is often elevated in major ... AIDS, and in the visceral fat of ...
Medicine Products: